Novo Nordisk and Fangzhou Unveil AI-Driven Diabetes and Weight Management Program at CIIE
SHANGHAI, Nov. 07, 2025 — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-powered Internet healthcare solutions, participated in the “Boundless Care, New Beginnings” 2025 Health Ecosystem Partner Alliance Summit and New Product Launch Ceremony. The event, hosted by Novo Nordisk, took place at the 8th China International Import Expo (“CIIE”) in Shanghai.
Novo Nordisk announced the expansion of its Health Ecosystem Alliance, which was initially introduced in 2023. Fangzhou was honored as an “Outstanding Strategic Health Ecosystem Partner,” recognizing its pivotal role in advancing digital innovation in chronic disease management.
Fangzhou was designated an “Outstanding Strategic Health Ecosystem Partner”
The “Health Ecosystem Alliance” functions as a collaborative platform, fostering joint development and synergies among its partners. As a core member, Fangzhou shares Novo Nordisk’s vision for advancing digital innovation in chronic disease management. In July 2025, the two companies formalized a strategic partnership aimed at better aligning service offerings with patient needs, thereby jointly developing digital chronic disease management models that empower healthcare stakeholders and benefit patients. Moving forward, Fangzhou plans to work closely with Novo Nordisk to establish a comprehensive digital chronic disease management ecosystem, driving continuous innovation and development in the healthcare sector.
Fangzhou has established itself as a leader in integrating AI technology into weight management, having developed the industry’s first intelligent “AI + Weight Management” solution. The company was also chosen as a key participant in the national “Healthy China: AI + Weight Management Initiative.” This initiative, in collaboration with the China Food and Drug Institutions Quality and Safety Promotion Association, seeks to promote standardization, technological advancement, and evidence-based methodologies.
Concurrently, Fangzhou has reinforced its capabilities in AI-powered diabetes management, earning strong recognition from Novo Nordisk for its proficiency in AI-driven healthcare services and medication management. By leveraging Fangzhou’s digital infrastructure and Novo Nordisk’s innovative therapies for diabetes and obesity, the two companies are collectively driving a shift from “disease-focused treatment” towards “proactive health management.” Novo Nordisk described this collaboration as a significant milestone in integrating chronic disease prevention with digital innovation, charting a new course for intelligent healthcare transformation.
Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, commented: “As a crucial partner within Novo Nordisk’s Health Ecosystem Alliance, Fangzhou will continue to utilize our XJ and XS Large Language Models as the foundation of our AI infrastructure. This will enable us to deepen technological innovation and deliver accessible, efficient, end-to-end chronic disease management services to a broader population.”
Throughout 2025, Fangzhou has consistently expanded and enhanced its AI + Chronic Disease Management ecosystem, facilitating the industry’s transition from traditional care models to systematized, evidence-based approaches. Through an open and collaborative strategy, the Company intends to partner with industry leaders to improve the quality and efficiency of digital healthcare, thereby significantly contributing to the Healthy China 2030 goals.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a prominent global healthcare company founded in 1923. Novo Nordisk’s core purpose is to drive change to overcome serious chronic diseases, building on its heritage in diabetes. The company achieves this by pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure disease.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025. The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, please visit .
Media Contact
For further inquiries or interview requests, please contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.
A photo accompanying this announcement is available at:
